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Abstract
Background: Patient-reported outcome (PRO) measures can be used to support label claims if they adhere to
US Food & Drug Administration guidance. The process of developing a new PRO measure is expensive and time-
consuming. We report the results of qualitative studies to develop new PRO measures for use in clinical trials of
omecamtiv mecarbil (a selective, small molecule activator of cardiac myosin) for patients with heart failure (HF), as
well as the lessons learned from the development process.
Methods: Concept elicitation focus groups and individual interviews were conducted with patients with HF to
identify concepts for the instrument. Cognitive interviews with HF patients were used to confirm that no essential
concepts were missing and to assess patient comprehension of the instrument and items.
Results: During concept elicitation, the most frequently reported HF symptoms were shortness of breath, tiredness,
fluid retention, fatigue, dizziness/light-headedness, swelling, weight fluctuation, and trouble sleeping. Two measures
were developed based on the concepts: the Heart Failure Symptom Diary (HF-SD) and the Heart Failure Impact
Scale (HFIS). Findings from cognitive interviews suggested that the items in the HF-SD and HFIS were relevant and
well understood by patients. Multiple iterations of concept elicitation and cognitive interviews were needed based
on FDA request for a broader patient population in the qualitative study. Lessons learned from the omecamtiv
mecarbil PRO/clinical development program are discussed, including challenges of qualitative studies, patient
recruitment, expected and actual timelines, cost, and engagement with various stakeholders.
Conclusion: Development of a new PRO measure to support a label claim requires significant investment and early
planning, as demonstrated by the omecamtiv mecarbil program.
Keywords: Patient-reported outcome, Qualitative research, Heart failure, FDA guidance, Instrument development,
Omecamtiv mecarbil
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Background
In a patient-centered healthcare system, incorporating
the patient’s perspective in research has become a prior-
ity [1, 2]. Patient-reported outcome (PRO) data may be
used to support label claims for promotional purposes
and/or scientific dissemination under specific guidance
from the US Food and Drug Administration (FDA) [3, 4]
and in general by the European Medicines Agency
(EMA) [5]. The specific guidance from the FDA was
published in 2009 [3], and the FDA’s Patient-Focused
Drug Development Initiative was developed in 2013 [4].
Pharmaceutical companies may use PRO information to
distinguish a product from a competing product, and to
contribute to discussions with Health Technology Assess-
ment (HTA) agencies and payers to support reimburse-
ment decisions [6, 7]. An important aspect of a clinical
program is to use tools that enable patients’ symptoms
and symptom impacts on their lives to be captured and
quantified. PROs are therefore essential in providing a
metric by which treatment success can be measured.
Current regulatory requirements for PRO measures to
be used in clinical trials are not consistent between regu-
latory agencies. The FDA has issued the most specific
and stringent guidance to be considered in the develop-
ment of PRO measures intended for use in label claims
[3], while the EMA has published a reflection paper on
the use of health-related quality of life measures in drug
evaluations [5]. To support a labeling claim in the US, a
PRO endpoint must be at least a pre-specified key sec-
ondary endpoint [3], whereas the EMA suggests that the
PRO endpoint be driven by an a priori formulated hy-
pothesis and detailed in the statistical analysis plan of a
clinical trial that is suitably powered for the PRO ana-
lysis [5]. Because of these differences, sponsors must
take differing regional agency requirements into consid-
eration in global development programs.
An important component of the FDA guidelines is that
a PRO measure must demonstrate content validity,
which is the extent to which the instrument measures
the concept of interest. In addition, the FDA specifies
that a PRO instrument needs to be well defined, reliable,
used in accordance with the instrument’s documented
measurement capability, and to have demonstrated val-
idity in the target patient population [3]. Several descrip-
tions of the process recommended in the development
of a good quality PRO measure have been published
[8–11], but reports of the practical considerations of in-
tegrating development of a PRO measure into a clinical
program are rare.
The importance of integrating a PRO measure in ran-
domized clinical trials (RCTs) of drugs for the treatment
of cardiovascular disease (CVD) has recently been
highlighted [6]. It is important that patients are able to
describe the impact of a novel treatment on their
symptoms, functions, and health-related quality of life
using scientifically sound PRO measures in CVD RCTs.
Since the release of the FDA PRO guidance, no sponsor
has achieved a PRO label claim for the treatment of
chronic HF (CHF), even though old label claims for car-
vedilol and other products exist. PROs developed prior
to the guidance may have been acceptable as label claims
in the past. However, a recent literature review of PROs
for chronic HF patients concluded that none of the
existing disease-specific PRO instruments for HF satisfy
all criteria outlined in the current FDA guidance [12],
and therefore may no longer be considered adequate to
support label claims.
The goal of this paper is to present the steps for inte-
grating the development of PRO measures into a clinical
drug development program with the aim of achieving a
label claim with the FDA on the severity of symptoms
and their impact on functioning for patients with HF.
We will provide real-world examples of the processes,
challenges, solutions, and lessons learned as part of the
development of a symptom and impact measure inte-
grated into a HF clinical trial program for omecamtiv
mecarbil. Omecamtiv mecarbil is a selective, small mol-
ecule activator of cardiac myosin [13] that has been
demonstrated to increase cardiac performance in animal
models [14], healthy human volunteers [15], and patients
with CHF [16].
Process required for pro development: a real-world
example
PROs can extend the insights of a product in develop-
ment beyond mortality and morbidity benefits, by de-
scribing the impact of treatment from the patient’s
perspective. Development of a PRO strategy must be
considered early in a product’s clinical development pro-
gram and a decision to develop a new PRO measure
needs to be made as early as when phase 1 clinical stud-
ies are conducted. Before a decision to develop a new
PRO instrument can be made, information such as past
PRO labels and PRO development activities of products
in the same therapeutic area, and the incremental com-
mercial value of PROs are often considered. This defines
the first step in PRO development, which is to conduct
an extensive literature review to survey existing instru-
ments, including a review of psychometric characteris-
tics (reliability, validity, ability to detect change) of these
measures and whether a label claim based on the mea-
sures has been successful (Fig. 1). A gap analysis of exist-
ing instruments will identify the extent to which they
meet FDA PRO guidance criteria. Three possible out-
comes of the literature review are: identification of a
suitable PRO measure; identification of a measure that
only needs modification; or a need to develop a new
PRO measure. If the decision is made to develop a new
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PRO measure, a PRO committee comprising clinical
experts in the therapeutic area of interest and PRO
development experts should be formed.
Omecamtiv mecarbil experience: A literature review
and gap analysis [12] was conducted after completion
of phase I and phase IIa studies of omecamtiv
mecarbil [15, 16]. The results of the review identified
multiple PRO measures for HF symptoms and
impacts, but none was considered to meet fully the
criteria put forward by the FDA in the PRO guidance
document for use in a clinical trial to support a label
claim, particularly due to gaps in documentation of
content validity [3]. The FDA is most favorable of
direct measures of symptoms and physical limitations
as opposed to more abstract concepts of social
limitations and patients’ perceptions of their quality of
life [3]. Therefore, a decision was made to develop two
new measures: one to assess the symptoms of CHF and
one to assess the impact of symptoms on functioning. A
PRO development committee of clinical and PRO
experts was formed.
Lessons learned: The number of existing PRO
measures and the extensive use of existing PRO
measures do not guarantee that any existing measure
meets current FDA PRO guidance criteria [12].
If a suitable measure is not found, the next step is to
conduct qualitative research to identify concepts for
the instrument and document content validity. Con-
tent validity shows that each of the items/domains of
an instrument is appropriate and comprehensive rela-
tive to its intended measurement concept, population,
and use [3]. Concept elicitation is a process that has
been used to identify key concepts related to an indi-
vidual patient’s symptoms and functioning with respect
to the disease and treatment, with an effort to capture
the patients’ experiences using their own words [10].
Concept elicitation can be based on focus groups or
individual interviews, or preferably using both. Re-
cruitment of a representative population in terms of
demographic and clinical characteristics of the target
population (including gender, ethnicity, educational
level, symptom severity, comorbid conditions, etc.)
represent important aspects to be taken into account.
Concept elicitation is considered to be complete when
saturation of concepts is achieved, defined as the point
at which no substantially new themes, descriptions of a
concept, or terms are introduced with additional
Fig. 1 Key steps in the process of developing a PRO measure. Multiple iterations of concept elicitation, item generation, and cognitive interviews
may be required (dashed arrows)
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interviews [17]. When concept elicitation is completed,
the PRO instrument is drafted.
Omecamtiv mecarbil experience: An institutional
review board (IRB)-approved qualitative study was
conducted; patients provided written informed consent
before initiation of study-related activities. One-on-one
concept elicitation interviews and focus groups were
conducted by trained interviewers and moderators
using semi-structured interview guides. Each session
was recorded and subsequently transcribed for analysis
using qualitative analysis software. An open coding
approach was used in the analysis. Additional concept
elicitation interviews were conducted until saturation
was achieved.
Three concept elicitation focus groups and six
individual interviews were conducted with 19 US
adults with CHF (mean age 73.8 [standard deviation
(SD) = 13] years; 21 % female; 79 % white; 11 % New
York Heart Association [NYHA] class IV disease). The
most frequently reported symptoms due to HF in
concept elicitation focus groups and interviews were
shortness of breath (reported by 74 % of patients),
tiredness (58 %), fluid retention (58 %), fatigue (47 %),
dizziness/light-headedness (32 %) swelling (32 %),
weight fluctuation (26 %), and trouble sleeping (21 %).
Other symptoms mentioned by less than 20 % of
participants included difficulty concentrating, muscle
problems (pain, cramps, numbness), loss of appetite,
and bloating. Concept saturation of symptoms was
reached by the end of the interviews.
HF had the greatest negative impact on physical
(difficulty walking [58 %], needing frequent rests
[54 %], reduced ability to do household chores [37 %]),
social (reduced social/family interactions [37 %],
participation in recreational activities/hobbies
[26 %]), and emotional (frustration stemming from
diminished ability or inability to complete activities
[26 %]) domains. Other impacts on functioning
mentioned by less than 20 % of participants
included difficulty carrying/lifting objects, running,
feeling dependent on others, dressing, impacts on
intimate relationships, depression, and mood swings.
Concept saturation of impacts was reached by the
end of the interviews.
Initial item pools of two HF measures, the Heart
Failure Symptom Diary (HF-SD) and Heart Failure
Impact Scale (HFIS), were created based on the results
of the concept elicitation focus groups and interviews,
along with experts, and input from PRO, translation,
and clinical experts, and a review of available
literature. All items were programmed in an electronic
device for further testing.
Lessons learned: A recruitment strategy to ensure
inclusion of patient groups that are difficult to recruit
(e.g., female patients with CHF and patients with
severe [NYHA class IV] disease) is an important
consideration at the early stages of development,
but can present practical challenges by slowing the
development process. Use of a recruitment tracker
and continuous contact with study sites to understand
which patients are available are helpful strategies,
as is securing back-up sites. Close relationships with
hospital settings may enhance recruitment of patients
with acute and severe disease.
After drafting an initial item pool based on the results
of concept elicitation, cognitive interviews are conducted
to confirm that no important concepts are missing in
the draft instrument and that the respondents under-
stand the wording and intended meaning of the items.
Results from the cognitive interviews are used to revise
the instrument. The purpose of cognitive interviews is
to assess the patient’s comprehension of the instru-
ment and the items and response options relative to
their intended meaning and to assess the comprehen-
siveness of content to ensure that no important items
are missing that would influence evaluation of the
targeted concept [11].
Omecamtiv mecarbil experience: Cognitive
interviews using the HF-SD and HFIS electronic
PRO (ePRO) measures were conducted with 18
adult US patients with CHF (mean age 68.8
[SD = 12] years, 33 % female, 83 % white, 22 %
NYHA class IV disease). Findings from the cognitive
interviews suggested that items of the HF-SD and
HFIS were relevant and well understood by patients
with CHF. Response options were also well understood
and appropriate for the items. The recall periods for the
HF-SD and HFIS were adequate for recollection of
symptom experience and impacts due to HF. Results
from cognitive interviews also suggested the need for
two additional items of impacted activities: indoor and
outdoor activities were changed to separate items, and
lifting and carrying were changed to separate items.
Some items were reworded for clarity.
Lessons learned: Achieving saturation of concepts in the
concept elicitation focus groups and interviews ensured
that no new concepts were found in the cognitive
interviews, and only the separation of related items was
needed for the HF-SD and HFIS following the cognitive
interviews.
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A key feature of PRO development is the iterative na-
ture of the process. Multiple waves of concept elicitation
and cognitive interviews may be required to achieve sat-
uration and sufficient evidence of content validity. Early
engagement of the FDA in the PRO development
process is important to ensure that the evidence for
content validity is considered to be acceptable.
Omecamtiv mecarbil experience: Results of concept
elicitation interviews and cognitive interviews were
presented to the FDA with request for feedback on the
presented evidence in support of the content validity
of the two measures. A second round of concept
elicitation interviews and cognitive interviews was
suggested by the FDA to solicit input from patients
with specific demographic (women, African Americans)
and clinical (NYHA class IV disease) characteristics.
Additional concept elicitation interviews were
therefore conducted with 15 US adults with CHF
(mean age 59.7 [SD = 10.8] years; 73 % female; 47 %
white; 13 % NYHA class IV disease). No participants
were included in both rounds of qualitative interviews.
The second round of concept elicitation interviews
supported the concepts endorsed in the first round of
interviews, no new concepts were identified, and no
changes were made to the instruments. Additional
cognitive interviews were conducted with ten
additional US adults with CHF (mean age 68.6
[SD = 9] years; 30 % female; 40 % white; 20 %
NYHA class IV disease). The findings from the
additional cognitive interviews demonstrated that
items of the HF-SD and the HFIS were well understood
and relevant to CHF patients, supporting the findings
of the initial cognitive interviews.
Lessons learned: A challenge was the recruitment of
patients with NYHA class IV disease outside of large,
specialized academic centers, as current treatment
regimens are effective and prevent development of HF
to this stage in many patients. While theoretically
important, the successful saturation of concepts in the
initial round of qualitative studies meant that no new
concepts were identified in the second round.
The final step in the development of a PRO measure is
to perform a quantitative study to identify the final set
of items, to further document content validity, and to
assess the measurement properties. The PRO can be
implemented in a proof-of-concept study or in a stand-
alone study for validation purposes [3]. Stand-alone
studies (which can also be run in parallel with a phase 2
trial) are designed to focus on assessment of the meas-
urement properties of the instrument; however, they are
costly, increase timelines, and do not provide
information on effects of treatment. There are, however,
situations where a stand-alone trial may be necessary,
such as when a highly effective treatment provides rapid
improvement, and there may not be a sufficient number
of stable subjects between study visits, or when the deci-
sion to develop a PRO is made after the phase 2 study
has already been started. The incorporation of PRO test-
ing in a phase 2 clinical trial is cost- and time-efficient,
and provides information on the drug being tested as
an added benefit. Altogether these aspects represent
advantages compared to a stand-alone study. Additional
considerations for use in a clinical trial are the mode of
administration (e.g., ePRO vs pencil and paper), and
translations and cross-cultural issues for global trials.
Without evidence of validity, reliability, responsiveness,
and interpretability of an instrument prior to its use in
pivotal trials, results will likely not be acceptable to
regulatory bodies.
Omecamtiv mecarbil experience: The HF-SD and HFIS
measures were piloted in a phase 2 trial to assess
item performance in order to identify and select the
final instrument items. This trial also provided the
opportunity for an initial assessment of the psychometric
properties of the final measures. The measures were
administered as ePRO assessments, which were initially
tested as part of the cognitive interviews, and enabled
an assessment of the usability of electronic data capture
in HF patients in advance of proceeding with the
electronic mode of administration in the phase 3
clinical trial. In addition to providing initial evidence
of the measurement properties of the HF-SD and the
HFIS, this step provides additional evidence for the mea-
sure’s content validity.
Lessons learned: Including ePRO administration in the
cognitive interview phase provided information on
usability and avoided a study to assess concordance
between paper and ePRO modes of administration,
which is time- and cost-consuming. Testing for
feasibility and ease of use of ePRO administration
early in development is useful before embarking on
its use in clinical trials.
Practical and logistical issues: key learnings from the
omecamtiv mecarbil clinical program
Timelines
Timelines must be carefully considered for the integra-
tion of PRO development within a clinical trial pro-
gram (Fig. 2). Factors that impact timelines include:
designing the study; sponsor reviews; IRB interactions
(which require extra time in academic settings); vendor
contracts; design and implementation of PRO instru-
ments (both paper and electronic versions); patient
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recruitment; translations; and communication with
regulatory agencies.
Omecamtiv mecarbil experience: The expected and
actual timelines of HF PRO development stages are
presented in Fig. 2. Early planning in our program led
to successful completion of the first round of
qualitative interviews and drafting of instruments
before the start of phase 2. Work on the PRO strategy
for the omecamtiv mecarbil clinical development
program started in 2012 and was expected to be
completed by 2013. Several factors caused delays in
the original timeline, including the need for a second
round of concept elicitation interviews and cognitive
interviews, difficulties with recruitment of patients
with NYHA class IV disease for qualitative interviews,
and the urgency and priority status of the drug.
Another factor was related to potential difficulty in
identifying clinical sites that could help recruit the
population of interest within the desired timeframe.
Sites using local IRBs usually require lengthier
contracting and review processes than sites with
central IRBs.
Lessons learned: An early start is critical as delays
in the original timeline are likely. Sponsors should
anticipate and plan for a second round of qualitative
studies, including strategies for recruitment of specific
types of patients.
Cost
The development of a new PRO instrument and the in-
corporation and use of the instrument in clinical trials is
expensive, and the final cost is difficult to estimate.
For example, in 2011 the total cost estimate of devel-
oping a new PRO instrument ranged from $725,000
to $2,150,000 [18]. Factors that significantly affect
cost are shown in Table 1.
Omecamtiv mecarbil experience: The planning of the
PRO strategy for the omecamtiv mecarbil clinical
development program started in 2011 with a literature
review and the initial budget for the PRO development
was within the cost estimate published in 2011. The
need to update the literature review prior to regulatory
submission, and to conduct a second round of concept
elicitation interviews and cognitive interviews and
secondary collection of clinical data from the first
round of interviews based on FDA feedback
adversely affected the timeline and increased the
cost. With careful planning we have managed to
save costs by including the ePRO measure in the
phase 2 clinical trial, thus eliminating the need for
a stand-alone study.
Lessons learned: The iterative nature of qualitative
studies can easily increase costs, but this can be
offset by initiating ePRO development early in the
planning process.
Fig. 2 (a) Hypothetical and (b) actual timelines of PRO instrument development. aIncluded second literature review. PRO, patient-reported out-
come; CE, concept elicitation; CIs, cognitive interviews; FDA, Food and Drug Administration; HF-SD, Heart Failure Symptom Diary; HFIS, Heart Fail-
ure Impact Scale
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Engagement with various stakeholders
Many people and agencies are involved in the develop-
ment of a PRO measure. Patients with the disease of
interest are traditionally included as participants in con-
cept elicitation interviews and cognitive interviews, and
there is a current shift toward partnership between
study sponsors and patients in research. Practicing
clinicians are included in the development process to
comment on clinical perspectives. In our experience,
it is helpful to obtain feedback from the FDA early in
PRO development.
Omecamtiv mecarbil experience: A PRO committee
was formed to oversee development of the new
instruments. Patients with CHF were involved in
concept elicitation and cognitive interview studies.
Within the sponsor organization, representatives
from Health Economics and Outcomes Research,
Biostatistics, Commercial, Clinical Development, and
Regulatory Affairs departments contributed to the
PRO development program. Qualitative studies were
designed and implemented by a vendor. FDA review
and feedback was solicited. Clinician and payer
feedback were solicited through market/payer
research advisory boards and 1:1 interviews.
Lessons learned: Involvement of multiple stakeholders
in PRO development ensures and improves the quality
of the final measure and contributes to better
understanding of the role a PRO can play in clinical
trials for involved parties. Careful planning and
management of the practical aspects of stakeholder
involvement is critical for the success of the program.
Discussion and conclusions
A recent paper from Anker et al. [6] highlights the im-
portance of integration of PRO measures in clinical trials
and notes that currently PROs are not routinely included
in CVD trials with the intent to support label claims.
The authors advocate for an increased focus on the
inclusion of scientifically sound PRO measures in CVD
trials. While the Anker paper provides some broad rec-
ommendations and considerations in the design of clin-
ical trials with the integration of a PRO, it does not
provide specific details on the practical challenges and
solutions for including PROs that can support labeling
claims. This also applies to the recent publications by
Thompson et al. and Garin, et al., which provide reviews
of the use of HF PROs in HF trials [2, 19]. While exist-
ing publications describing the development and psycho-
metric evaluation of PRO measures provide detailed
theoretical steps, they rarely address the practical chal-
lenges and decision-making required in the process. Our
report builds on the broad consideration from the
Anker paper and provides a specific practical example
of the integration process and an insight into the les-
sons learned.
Several governmental, nongovernmental and profes-
sional organizations have recognized the value of PROs
and are actively developing or acknowledging the need
to develop disease-specific PRO instruments for both
regulatory approval and quality assessment. In 2005, the
National Institutes of Health (NIH) established the
Patient Reported Outcomes Measurement Information
System (PROMIS), comprising multiple item banks built
on existing instruments measuring a range of outcomes.
PROMIS is currently used by various US governmental
agencies (including the FDA) to assist with development
and quality assessment of PRO measures [20]. In 2012,
the Centers for Medicare and Medicaid Services (CMS)
funded the National Quality Forum (NQF) to develop
guidance on PRO measures based on the National Quality
Strategy (NQS) to improve medical care for individuals
[21]. The CMS now considers the patient perspective in
the development of all PRO measures [20]. The Critical
Path Institute (C-Path) is a nonprofit, public-private
Table 1 Factors that affect the cost of PRO development
Factor Considerations
Patient and site recruitment Use of vendors to identify and recruit patients, payment for participation in
qualitative studies, ease of access to target patient groups
Multiple stakeholder involvement PRO experts, IRBs, clinicians, patients, researchers, PRO and ePRO vendors
Number of iterations Multiple rounds of concept elicitation interviews and cognitive interviews to
achieve saturation of concepts and satisfactory evidence of content validity
Delays in clinical program unrelated to PRO development Need to update reviews prior to regulatory approval, increased risk of staff
changes reducing efficiency of process
Approach selected for quantitative validation Stand-alone vs regular clinical trials
Mode of instrument administration ePRO vs pencil and paper vs mixed mode; need to demonstrate instrument
equivalence
Clinical trial design Number of languages and cultural adaptations needed
Dissemination strategies Dossier preparation, conference presentations, manuscripts, etc.
PRO patient-reported outcome, IRBs Institutional Review Boards
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organization that partners with the FDA, PRO re-
searchers, pharmaceutical companies, and the NIH to
develop data standards, measurement standards, and
methods standards to evaluate new therapies [22]. In
2013, the American Heart Association (AHA) pub-
lished a scientific statement emphasizing the import-
ance of measuring patients’ health status using PROs
[23], followed by a similar endorsement by the European
Society of Cardiology (ESC) a year later [6]. Other profes-
sional societies have been involved in activities to further
scientific development of cardiovascular assessment
measures [24, 25]. Notably, the Patient-Centered Out-
comes Research Institute (PCORI) has funded an effort
to develop PROMIS Condition-Specific Impact Assess-
ment (PROMIS-CSIA) for patients with HF and osteo-
arthritis [26]. All PCORI-funded studies require
engagement of patients as collaborators as a condition
for funding.
Developing a new PRO measure in accordance with
the FDA PRO guidance to support a label claim requires
significant investment and early planning in the devel-
opment of a clinical trial program. In this paper, a
real-world example in the area of HF was provided to
illustrate some of the successes and challenges experi-
enced and to report on the methods of PRO develop-
ment for HF symptom and impact measures.
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